Status:
COMPLETED
A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn about an investigational drug known as oral lipoic acid (LA) that may help treat multiple sclerosis. This study will measure how a person's body absorbs and break...
Detailed Description
Multiple sclerosis (MS) is a common, often disabling inflammatory disease of the central nervous system (CNS). Present treatments for MS are only partially effective, available only in injectable form...
Eligibility Criteria
Inclusion
- Definite MS by McDonald's or Poser's criteria
- EDSS ≤ 7.5
- Age 18 to 80
Exclusion
- No clinically significant MS exacerbation within 30 days of the screening
- No systemically administered corticosteroids within 30 days of study entry
- Patient not pregnant or breast feeding
- No LA in previous 2 weeks
- Not on anti-coagulants such as heparin, coumadin, or aspirin during study
- No other significant health problem (e.g. active coronary heart disease, liver disease, pulmonary disease, diabetes mellitus) that might increase risk of patient experiencing adverse events
- Inability to give informed consent
- Any condition which would make the patient, in the opinion of the investigator, unsuitable for the study
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00676156
Start Date
December 1 2005
End Date
November 1 2008
Last Update
November 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health and Science University Multiple Sclerosis Dept.
Portland, Oregon, United States, 97239